Update of results of autologous bone marrow transplantation in lymphoma

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

A substantial proportion of patients with Hodgkin’s disease and non-Hodgkin’s lymphoma will fail to achieve a complete remission with initial chemotherapy or will relapse after attaining a complete remission. The results of conventional salvage chemotherapy regimens for these patients have been disappointing. This has led to the use of highdose therapy regimens which can be administered with the use of hematopoietic rescue (bone marrow transplantation). The use of bone marrow transplantation for patients with relapsed and refractory lymphoma has increased rapidly. Data from the North American Autologous Bone Marrow Transplant Registry indicate that approximately 40 % of autologous bone marrow transplants are being performed for patients with lymphoma. Several large series of transplantation for Hodgkin’s disease and non-Hodgkin’s lymphoma have been published in the last two years1-12. The results of these series vary widely due to differences in patient selection and pre-transplant prognostic factors. Differences in supportive care and preparative regimens prior to transplant may also account for the wide range of outcomes reported after transplantation. Although these differences make it impossible to compare results of one series with another, it is clear that a significant proportion of patients can achieve long term disease free survival following high dose therapy with marrow transplantation. It is also important, however, to note that this form of therapy can be associated with substantial morbidity and mortality. Transplant-related mortality exceeds 20 % in some series. However, greater experience, better patient selection, and advances in supportive care, such as hematopoietic growth factors, are allowing many institutions to perform transplantation with mortality rates under 5 %.

Original languageEnglish (US)
Pages (from-to)35-41
Number of pages7
JournalMedical Oncology
Volume11
Issue number2
DOIs
StatePublished - Jan 1 1994

Fingerprint

Autologous Transplantation
Bone Marrow Transplantation
Lymphoma
Transplants
Transplantation
Bone Marrow
Hodgkin Disease
Non-Hodgkin's Lymphoma
Patient Selection
Mortality
Drug Therapy
Disease-Free Survival
Registries
Intercellular Signaling Peptides and Proteins
Therapeutics
Morbidity
Recurrence

Keywords

  • Bone marrow transplantation
  • lymphoma

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Cite this

Update of results of autologous bone marrow transplantation in lymphoma. / Bierman, Philip Jay.

In: Medical Oncology, Vol. 11, No. 2, 01.01.1994, p. 35-41.

Research output: Contribution to journalArticle

@article{a135668715f646509e25ad2532dd6f8c,
title = "Update of results of autologous bone marrow transplantation in lymphoma",
abstract = "A substantial proportion of patients with Hodgkin’s disease and non-Hodgkin’s lymphoma will fail to achieve a complete remission with initial chemotherapy or will relapse after attaining a complete remission. The results of conventional salvage chemotherapy regimens for these patients have been disappointing. This has led to the use of highdose therapy regimens which can be administered with the use of hematopoietic rescue (bone marrow transplantation). The use of bone marrow transplantation for patients with relapsed and refractory lymphoma has increased rapidly. Data from the North American Autologous Bone Marrow Transplant Registry indicate that approximately 40 {\%} of autologous bone marrow transplants are being performed for patients with lymphoma. Several large series of transplantation for Hodgkin’s disease and non-Hodgkin’s lymphoma have been published in the last two years1-12. The results of these series vary widely due to differences in patient selection and pre-transplant prognostic factors. Differences in supportive care and preparative regimens prior to transplant may also account for the wide range of outcomes reported after transplantation. Although these differences make it impossible to compare results of one series with another, it is clear that a significant proportion of patients can achieve long term disease free survival following high dose therapy with marrow transplantation. It is also important, however, to note that this form of therapy can be associated with substantial morbidity and mortality. Transplant-related mortality exceeds 20 {\%} in some series. However, greater experience, better patient selection, and advances in supportive care, such as hematopoietic growth factors, are allowing many institutions to perform transplantation with mortality rates under 5 {\%}.",
keywords = "Bone marrow transplantation, lymphoma",
author = "Bierman, {Philip Jay}",
year = "1994",
month = "1",
day = "1",
doi = "10.1007/BF02988828",
language = "English (US)",
volume = "11",
pages = "35--41",
journal = "Medical Oncology and Tumor Pharmacotherapy",
issn = "1357-0560",
publisher = "Humana Press",
number = "2",

}

TY - JOUR

T1 - Update of results of autologous bone marrow transplantation in lymphoma

AU - Bierman, Philip Jay

PY - 1994/1/1

Y1 - 1994/1/1

N2 - A substantial proportion of patients with Hodgkin’s disease and non-Hodgkin’s lymphoma will fail to achieve a complete remission with initial chemotherapy or will relapse after attaining a complete remission. The results of conventional salvage chemotherapy regimens for these patients have been disappointing. This has led to the use of highdose therapy regimens which can be administered with the use of hematopoietic rescue (bone marrow transplantation). The use of bone marrow transplantation for patients with relapsed and refractory lymphoma has increased rapidly. Data from the North American Autologous Bone Marrow Transplant Registry indicate that approximately 40 % of autologous bone marrow transplants are being performed for patients with lymphoma. Several large series of transplantation for Hodgkin’s disease and non-Hodgkin’s lymphoma have been published in the last two years1-12. The results of these series vary widely due to differences in patient selection and pre-transplant prognostic factors. Differences in supportive care and preparative regimens prior to transplant may also account for the wide range of outcomes reported after transplantation. Although these differences make it impossible to compare results of one series with another, it is clear that a significant proportion of patients can achieve long term disease free survival following high dose therapy with marrow transplantation. It is also important, however, to note that this form of therapy can be associated with substantial morbidity and mortality. Transplant-related mortality exceeds 20 % in some series. However, greater experience, better patient selection, and advances in supportive care, such as hematopoietic growth factors, are allowing many institutions to perform transplantation with mortality rates under 5 %.

AB - A substantial proportion of patients with Hodgkin’s disease and non-Hodgkin’s lymphoma will fail to achieve a complete remission with initial chemotherapy or will relapse after attaining a complete remission. The results of conventional salvage chemotherapy regimens for these patients have been disappointing. This has led to the use of highdose therapy regimens which can be administered with the use of hematopoietic rescue (bone marrow transplantation). The use of bone marrow transplantation for patients with relapsed and refractory lymphoma has increased rapidly. Data from the North American Autologous Bone Marrow Transplant Registry indicate that approximately 40 % of autologous bone marrow transplants are being performed for patients with lymphoma. Several large series of transplantation for Hodgkin’s disease and non-Hodgkin’s lymphoma have been published in the last two years1-12. The results of these series vary widely due to differences in patient selection and pre-transplant prognostic factors. Differences in supportive care and preparative regimens prior to transplant may also account for the wide range of outcomes reported after transplantation. Although these differences make it impossible to compare results of one series with another, it is clear that a significant proportion of patients can achieve long term disease free survival following high dose therapy with marrow transplantation. It is also important, however, to note that this form of therapy can be associated with substantial morbidity and mortality. Transplant-related mortality exceeds 20 % in some series. However, greater experience, better patient selection, and advances in supportive care, such as hematopoietic growth factors, are allowing many institutions to perform transplantation with mortality rates under 5 %.

KW - Bone marrow transplantation

KW - lymphoma

UR - http://www.scopus.com/inward/record.url?scp=0028072670&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028072670&partnerID=8YFLogxK

U2 - 10.1007/BF02988828

DO - 10.1007/BF02988828

M3 - Article

C2 - 7850262

AN - SCOPUS:0028072670

VL - 11

SP - 35

EP - 41

JO - Medical Oncology and Tumor Pharmacotherapy

JF - Medical Oncology and Tumor Pharmacotherapy

SN - 1357-0560

IS - 2

ER -